Anurag Relan

Also affiliated with Bayer (United States)

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome”.

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome

Blood(2022)10.1182/blood.2022018546

N/A

3.2DataRank · unranked

132 citations

Sharon Webster, Anna Šedivá, Alessandro Plebani, Catharina Schuetz, Anna Shcherbina +17 more

Interim analysis: Open-label extension study of leniolisib for patients with APDS

Journal of Allergy and Clinical Immunology(2023)10.1016/j.jaci.2023.09.032

N/A

1.2DataRank · unranked

40 citations

Elaine Kulm, Anna Šedivá, Alessandro Plebani, Catharina Schuetz, Anna Shcherbina +15 more

A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): Adolescent and adult subgroup analysis

Clinical Immunology(2024)10.1016/j.clim.2024.110400

N/A

0.434DataRank · unranked

17 citations

Anna Šedivá, Virgil A. S. H. Dalm, Alessandro Plebani, Catharina Schuetz, Anna Shcherbina +14 more